AZD5576(AZD 5576) is a potent, highly selective, and orally bioavailable inhibitor of CDK9 with IC50 of < 5 nM, decreases phosphorylation of Ser2-RNAPII in cells with an IC50 of 96 nM.

AZD-5248 is a potent, selective, first generation, oral inhibitor of dipeptidyl peptidase 1 (DPP1)..

AZD-4818 is a highly potent, selective CCR1 antagonist with pIC50 of 8.6, inhibits chemotaxia of human monocytes to MIP-1α in a concentration-dependent manner.

AZD4320 is a BH3 mimetic and dual Bcl-2/Bcl-XL inhibitor with IC50 of <1 nM.

AZD4017 is a potent, selective, and orally bioavailable human 11β-HSD1 with IC50 of 7 nM, shows no significant activity against 11β-HSD1 and 17β-HSD1, 17β-HSD3 (IC50>30 uM).

AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.

AZD-3161 is a potent and selective sodium channel Nav1.7 blocker for treatment of nociceptive pain. .

AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM; highly selective against multiple PI3K isoforms (α/β/γ/δ).

AZD-1305 is a novel antiarrhythmic agent that predominantly blocks the rapid component of IKr, the L-type calcium current, and the inward sodium current in mammalian cells and ventricular cardiomyocytes.

AZD-1092 (GKA-80) is a potent Glucokinase (GK) activator with EC50 of 30 nM.

AZD-0837 is a novel oral anticoagulant that after bioconversion to its active form is a potent and reversible thrombin inhibitor, has been investigated in phase II studies for prevention of stroke and systemic embolic events in patients with atrial fibril

AZD 7009 is a novel antiarrhythmic agent that inhibits the late sodium current in CHO K1 cells expressing hNav1.5 with IC50 of 11 uM.

AZD 6610 is a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist for treatment of diabetes mellitus..

AZD 3043 (THRX-918661) is a positive allosteric modulator of the GABAA receptor in vitro and a sedative/hypnotic agent in vivo, potentiates GABAA receptor-mediated chloride currents with EC50 of 36 uM.

AZD 1678 is a potent, selective orally bioavailable CCR4 receptor antagonist with pIC50 of 8.6 for hCCR4, pIC50 of 9.0 for rCCR4.

AZD 0424 is an orally bioavailable small molecule tyrosine kinase inhibitor of Abl and Src kinase with potential antineoplastic activity..

AZ8838 racemate(AZ-8838 racemate) is the racemate form of AZ8838, which is a potent, and selective PAR2 antagonist with Kd of 125 nM..

AZ-4217 is a potent and selective, orally active, brain-permeable BACE1 inhibitor with IC50 of 160 pM in human SH-SY5Y cells.

AZ-23 is a potent, selective, orally bioavailable Trk kinase inhibitor with IC50 of 2 and 8 nM for TrkA and TrkB, respectively.

AZ-2 is a small molecule inducer of ABCA1 and apoE that act through indirect activation of the LXR pathway, shows purinergic receptor P2X7 antagonist activity.

AZ1729 is a novel direct, positive allosteric modulator of fatty acid receptor FFA2 (pEC50=6.9), selectively activates Gi signaling but lacks the capacity to activate FFA2 Gq/G11-mediated signaling pathways.

AZ13711265 is a potent, selective, in vivo active PAK1 inhibitor with IC50 of 0.58 nM, displays 880-, 2100- and 90-fold selectivity over Src, FGFR1, KDR and PAK4.

AZ-1355 is an effctive lipid-lowering compound that inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro..

AZ12799734 (AZ-12799734) is a pan BMP/TGFβ inhibitor that potently inhibits ligand activated SMAD3/4 transcription with IC50 of 47 nM, inhibits receptor-mediated phosphorylation of SMAD1 by ALK1, BMPR1A and BMPR1B and phosphorylation of SMAD2 by ALK4, TGF

AZ12601011 (AZ-12601011) is a potent, selective inhibitor of ALK4, ALK7 and TGFBR1 (Kd=2.9 nM), inhibits TGFβ-induced reporter activity with IC50 of 18 nM.

AZ12441970 is a selective TLR7 agonist with pEC50 of 6.8 and 6.6 for human and rat TLR7, shows inactivity against TLR8.

AZ12204657 (AZ-12204657) small-molecule GPR44 antagonist, displaces the binding of [3H]PGD2 from membranes of HEK293 cells transfected with human recombinant GPR44 with IC50 of 2.5 nM.

AZ-1 is a small molecule inducer of ABCA1 and apoE that act through indirect activation of the LXR pathway, shows purinergic receptor P2X7 antagonist activity.

AZ0108 is an orally bioavailable phthalazinone PARP inhibitor with enzyme IC50 of <30/<30/83 nM for PARP1/2/6 respectively.

AZ 4800 is a potent γ-secretase modulator that reduces Aβ40 and Aβ42 levels in HEK/APPswe cells with IC50 of 26 nM and 60 nM, also decreases Aβ39, whereas increases both Aβ37 and Aβ38..